U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

	Application Number		10583996	
INFORMATION DIGGL COURT	Filing Date		2007-06-11	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Yechie		chici SHAI	
(Not for submission under 37 CFR 1.99)	Art Unit		1654	
,	Examiner Name	Ronal	ld T. Niebauer	
	Attorney Docket Numb	er	SHAI 8	

	U.S.PATENTS							
Examiner Initial*	Cite No			Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	5464933		1995-11-07	BOLOGNESI et al			
	2	5840843		1998-11-24	JIANG et al			
	3	6013263		2000-01-11	BARNEY et al			
	4	6017536		2008-09-05	BARNEY et al			
	5	6020459		2000-02-01	BARNEY et al			
	6	6093794		2000-07-25	BARNEY et al			
	7	6133413		2000-10-17	MOURI et al. BOLOGNESI et al			
	8	6133418		2000-10-17	BOLOGNESI et al			

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10583996
Filing Date		2007-06-11
First Named Inventor Yechi		hici SHAI
Art Unit		1654
Examiner Name Rona		ald T. Niebauer
Attorney Docket Number		SHAL8

	9	6228983		2001-05	5-08	BARNEY et al				
	10	6518013		2003-02-11		BARNEY et al				
If you wis	h to ac	ld additional U.S. Pater	t citatio	n inform	ation pl	ease click the	Add button.			
			U.S.P.	ATENT	APPLI	CATION PUBI	LICATIONS			
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	ition	Name of Pate of cited Docu	entee or Applicant ment	Rele	es,Columns,Lines where vant Passages or Relev res Appear	
	1									
If you wis	n to ac	ld additional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Add	d butte	on.	
				FOREIG	SN PAT	ENT DOCUM	ENTS			
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code4	Publication Date	Name of Patenter Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	Т5
	1	9428920	wo		A1	2008-09-05	DUKE UNIVERSIT	Y		
	2	9640191	wo		A1	1996-12-19	TRIMERIS INC.			
	3	03023013	WO		A2	2003-03-20	HYSEQ INC.			
If you wisl	h to ac	ld additional Foreign Pa	tent Do	cument	citation	information pl	ease click the Add	butto	n	
			NON	-PATEN	IT LITE	RATURE DO	CUMENTS			_
Examiner Initials*	Cite No	Include name of the au (book, magazine, journ publisher, city and/or of	nal, seria	al, symp	osium,	catalog, etc), o	the article (when a date, pages(s), volu	pprop ume-is	riate), title of the item ssue number(s),	T5

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10583996			
Filing Date		2007-06-11			
First Named Inventor	Yech	ci SHAI			
Art Unit		1654			
Examiner Name Ronal		ld T. Niebauer			
Attorney Docket Numl	er	SHAL8			

1	Eckert D. M. et al., "Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket". Cell 1999;99:103-115.	
2	Gerber D. et al., "Insertion and organization within membranes of the delta-endotoxin pore-forming domain, helix 4- loop-helix 5, and inhibition of its activity by a mutant helix 4 peptide". J Biol Chem. 2000 Aug 4:275(31):23602-7.	
3	Gerber D. et al., "In vivo detection of hetero-association of glycophorin-A and its mutants within the membrane". J Biol Chem. 2001 Aug 17;276(33):31229-32.	
4	Gerber D. et al., "Chirality-independent protein-protein recognition between transmembrane domains in vivo". J Mol Biol. 2002 Sep 20;322(3):491-5.	
5	Judice J.K. et al., "Inhibition of HIV type 1 infectivity by constrained alpha-helical peptides: implications for the viral fusion mechanism". Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13426-30.	
6	Kliger Y. et al., "Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage". J Biol Chem. 2001 Jan 12;276(2):1391-7.	
7	Kliger Y. et al., "Fusion peptides derived from the HIV type 1 glycoprotein 41 associate within phospholipid membranes and inhibit cell-cell Fusion. Structure-function study". J Biol Chem. 1997 May 23;272(21):13498-505.	
8	Lu M. et al., "A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein". J Biomol Struct Dyn. 1997 Dec;15(3):465-71.	
9	MacKenzie K. et al., "A transmembrane helix dimer: structure and implications". Science 1997,276: 131-133	
10	Manolios N. et al., "T-cell antigen receptor transmembrane peptides modulate T-cell function and T cell-mediated disease". Nat. Med. 1997;3:84-88.	
11	Melnyk Roman A. et al., "Retention of native-like oligomerization states in transmembrane segment peptides." Application to the Escherichia coli aspartate receptor. BIOCHEMISTRY, vol. 40, no. 37, 2001, 11108-11113.	

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10583996
Filing Date		2007-06-11
First Named Inventor Yechie		ci SHAI
Art Unit		1654
Examiner Name Rona		d T. Niebauer
Attorney Docket Numb	or	CHAIR

	12	Pritsker M. et al., "A synthetic all D-amino acid peptide corresponding to the N-terminal sequence of HIV-1 gp41 recognizes the wild-type fusion peptide in the membrane and inhibits HIV-1 envelope glycoprotein-mediated cell fusion". Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7287-92.						
	13	Rutledge T. et al., "Transmembrane helical interactions: zeta chain dimerization and functional association with the T cell antigen receptor". Embo J. 1992;11:3245-3254.						
	14	Russ W. P. et al., "The GxxxG motif: a framework for transmembrane helix-helix association". J. Mol. Biol. 2000;296: 911-919.						
	15	Sal-Man N. et al., "Hetero-assembly Between All-I- and All-I-Amino Acid Transmembrane Domains: Forces Involved and Implication for Inactivation of Membrane Proteins". JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 344, no. 3, 2004, 855-864.						
	16	Shal Y. et al., "Diastereoisomers of cytolysins, a novel class of potent antibacterial peptides".  J. Biol. Chem. 1996;271:7305-7308.						
	Shai Y. et al., "From "carpet" mechanism to de-novo designed diastereomeric cell-selective antimicrobial peptides". PEPTIDES (NEW YORK), vol. 22, no. 10, 2001, 1629-2641.							
	Wild C. et al., "A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion". AIDS Res Hum Retroviruses. 1993 Nov;9(11):1051-3.							
If you wis	h to a	d additional non-patent literature document citation information please click the Add button						
		EXAMINER SIGNATURE						
Examiner	Signa	ure /Ronald Niebauer/ Date Considered 04/06/2009						
		ital if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a						

itation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Codes of USPTO Patent Documents at www.USPTO\_COV or MPEP 9910.6. \*Enter office that issued the document, by the two-letter code (WPO-Standard ST3.) \*For Japanese patent documents, the indication of the year of the reign of the Emporer must proceed the serial more of the patent document, "kind of document by the appropriate symbols as indicated on the document under WiPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language stranslation is attached.